Talphera, Inc. (TLPH) secures $29 million through private placement agreements with CorMedix Inc. and institutional investors. CEO Vince Angotti highlights the funding’s significance in supporting potential Niyad PMA approval expected in the second half of next year. The investment underscores confidence in Niyad as a potential FDA-approved regional anticoagulant for CRRT. Talphera plans to issue over 25 million shares and nearly 6 million pre-funded warrants at $0.55 per share and $0.549 per warrant, respectively. CorMedix gains exclusivity for 60 days post NEPHRO CRRT results to negotiate a potential acquisition of Talphera. TLPH stock currently trades at $0.7127, up 29.7977% on NasdaqCM.

Read more at Nasdaq: Talphera Announces $29 Mln Private Placement Led By CorMedix And Institutional Investors